Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Acne Vulgaris: full-pipeline trial registry
2 of 68 indexed Acne Vulgaris trials are currently recruiting.
Corpus placement: #203 of 28,707 conditions by registered trial count.
68 US clinical trials · 2 currently recruiting · #203 of 28,707 conditions by registered trial count
Acne Vulgaris: 68 US clinical trials tracked, 2 recruiting.
Acne Vulgaris is the subject of 68 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 26 are in Phase 3-4 (later-stage) and 33 in Phase 1-2 (earlier-stage). The most active sponsor is Galderma R&D, running 7 of these trials.
Enrollment posture brief
Registry condition acne-vulgaris
OPEN 2 | RECR 3% | LATE 26 | EARLY 33 | RANK #203 | SPON 7
Volume-matched condition peers
Nearest open-share peer: Coronary Disease (3% recruiting · 36 trials)
Acne Vulgaris lists 2 open slots (3% of 68 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Acne Vulgaris on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Acne Vulgaris is recruiting below its size-band peers.
2 of 68 indexed trials (2.9%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Acne Vulgaris trials is spread across many organizations.
Galderma R&D accounts for 7 of 68 trials (10.3%). 38 distinct sponsors appear on at least one study for this condition label.
-
Typical Acne Vulgaris enrolment sits around 126 participants.
Median target enrolment is 126 among the 68 trials that report a genuine target (sentinel values excluded). 30 of those (44.1%) plan for fewer than 100 participants.
-
Acne Vulgaris research is mostly interventional.
66 interventional and 2 observational studies make up this index (97.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
68 total, page 1 of 2
Weekly Isotretinoin vs Tetracycline for Moderate Acne
Medical University of South Carolina
NCT06225570
Clascoterone for Steroid-related Acne Vulgaris in Transgender Male Patients Receiving Masculinizing Hormone Therapy
Stanford University
NCT05891795
Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults
Biofrontera
NCT05080764
A Post Market Device Study for the Treatment of Acne
Cutera
NCT06469398
Lipidome and Microbiome Profile of Acne
University of California, Davis
NCT02713607
Laser Treatment of Moderate to Severe Acne Vulgaris
Massachusetts General Hospital
NCT04466527
A Study to Assess Sebaceous Gland Changes and Constituents of Sebum (Skin Oil) Induced by Clascoterone 1% Cream in Acne Patients
Sun Pharmaceutical Industries Limited
NCT06425900
Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne
Almirall, S.A.
NCT02322866
A Study Comparing Trifarotene Cream 0.005% to AKLIEF® CREAM (US REFERENCE LISTED DRUG), AKLIEF™ CREAM (CANADIAN REFERENCE PRODUCT) in the Treatment of Acne Vulgaris
Sun Pharmaceutical Industries
NCT06733402
A Study Comparing Adapalene Gel 0.1% and to Differin Gel in the Treatment of Acne Vulgaris
Sun Pharmaceutical Industries
NCT04797793
A Study Comparing Tretinoin Gel Microsphere, 0.1% and RETIN-A MICRO ® Gel Microsphere, 0.1% in the Treatment of Acne Vulgaris
Sun Pharmaceutical Industries
NCT04883736
A Study Comparing Trifarotene Cream 0.005% to AKLIEF® Cream in the Treatment of Acne Vulgaris
Sun Pharmaceutical Industries
NCT06063473
A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris
Dermira
NCT03028363
A Long-term Safety Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris
Dermira
NCT03127956
A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris
Dermira
NCT03073486
A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne
Stiefel, a GSK Company
NCT01017120
Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel and Vehicle Gel
Bausch Health Americas
NCT04892706
Placebo Controlled Efficacy and Safety Study of CD2475/101 40 mg Tablets vs. Placebo and Doxycycline 100 mg Capsules Once Daily in the Treatment of Inflammatory Lesions of Acne Vulgaris
Galderma R&D
NCT01320033
An Open-Label, Long-Term Extension Study to Evaluate the Safety of CB-03-01 Cream, 1% in Participants With Acne Vulgaris
Cassiopea SpA
NCT02682264
P3 Long Term Safety Study of Once Daily SB204 in Acne
Novan
NCT02798120
Safety and Efficacy Study of Clindamycin/Benzoyl Peroxide/Tazarotene Cream in Subjects With Acne
Stiefel, a GSK Company
NCT00713609
Evaluate Safety and Efficacy of an OC Preparation vs Placebo for 6 Treatment Cycles in Women With Moderate Acne.
Bayer
NCT00651469
A Safety and Efficacy Evaluation of Topical Treatments for Moderate-Severe Facial Acne Vulgaris
Braintree Laboratories
NCT02604680
A Multi-Center Open-Label Evaluation of the Safety of Sarecycline Tablets in the Treatment of Acne Vulgaris
Almirall, S.A.
NCT02413346
A Study of S6G5T3 in the Treatment of Acne Vulgaris
Sol-Gel Technologies
NCT03761810
A Dose-ranging Study of DRM01 in Subjects With Acne Vulgaris
Dermira
NCT02431052
Clinical Trial in Subjects With Mild to Moderate Acne Vulgaris
AOBiome
NCT02832063
A Clinical Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris
Dow Pharmaceutical Sciences
NCT00666900
Efficacy and Safety of IDP-120 Gel in the Treatment of Acne Vulgaris
Bausch Health Americas
NCT03003247
A Study to Evaluate the Safety and Efficacy of Omiganan (CLS001) Topical Gel Versus Vehicle in Female Subjects With Moderate to Severe Acne Vulgaris
Maruho Co.
NCT02571998
Dose Range Study of CD5789 in Acne Vulgaris
Galderma R&D
NCT01616654
Light Dose Ranging Study of Photodynamic Therapy (PDT) With Levulan + Blue Light Versus Vehicle + Blue Light in Severe Facial Acne
DUSA Pharmaceuticals
NCT00706433
BPX-01 Minocycline Topical Gel in the Treatment of Acne Vulgaris
BioPharmX
NCT02815332
Cultural Differences in Treatment Preferences and Perceptions of Acne
Northwestern University
NCT03192163
A Study to Compare Efficacy and Safety of Trifarotene Cream When Used With an Oral Antibiotic for the Treatment of Severe Acne Vulgaris (AV)
Galderma R&D
NCT04451330
A Phase 2 Study of ASC-J9 Cream in Acne Vulgaris
AndroScience
NCT00525499
A Treatment for Severe Inflammatory Acne Subjects
Galderma R&D
NCT02899000
Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris
Bausch Health Americas
NCT04214639
Evaluation of Irritation That Potentially Could be Caused by Two Facial Gels Applied to Opposite Sides of the Face
Bausch Health Americas
NCT00952523
Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris
Xoma (US)
NCT01498874
U0289-405: An Open-Label, 12-Week Study to Evaluate the Efficacy and Safety of the Acne System (Benzoyl Peroxide 2.5%, Salicylic Acid 0.5%) in Subjects With Acne
Stiefel, a GSK Company
NCT01446237
AkLief Evaluation in Acne-induced Post-Inflammatory Hyperpigmentation
Galderma R&D
NCT05089708
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne Vulgaris
Vanda Pharmaceuticals
NCT04856917
Efficacy and Safety Study With Visonac Photodynamic Therapy (PDT)
Photocure
NCT00933543
Comparison Between Interactive Internet-based Education and Counseling for the Management of Acne With That of Internet-based Education Alone
University of California, Davis
NCT02031718
Long-term Follow-up Study of Subjects Who Completed Clinical Studies 755.1100_FA, 810.1100_FA, or 1064.1100_FA
Sienna Labs
NCT03039634
A Study of Dapsone Gel in Females With Skin of Color and Acne Vulgaris
Allergan
NCT02032407
Cutaneous Tolerability and Safety of NVN1000 Topical Gel in Healthy Volunteers
Novan
NCT01694810
A Thorough ECG Study in Subjects With Acne Vulgaris Treated With SB204
Novan
NCT02581072
Pharmacokinetic Study to Compare the Systemic Exposure of Differin® Gel, 0.3% or Differin® Gel, 0.1%
Galderma R&D
NCT00660985
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 13 |
| Phase 2 | 20 |
| Phase 3 | 12 |
| Phase 4 | 14 |
Top Sponsors
Named interventions
Most-linked intervention names on Acne Vulgaris records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Acne Vulgaris trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Acne Vulgaris page
68 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Acne Vulgaris trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Galderma R&D sponsors the most Acne Vulgaris trials on record, review their full trial history before evaluating a specific study. See Galderma R&D's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Acne Vulgaris condition card totals 68 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.